糖组
黑色素瘤
医学
免疫系统
外科肿瘤学
免疫学
肿瘤科
聚糖
生物标志物
糖基化
内科学
癌症研究
生物
糖蛋白
生物化学
分子生物学
作者
Alessia Visconti,Niccolò Rossi,Helena Deriš,Karla A. Lee,Maja Hanić,Irena Trbojević‐Akmačić,Andrew Maltez Thomas,Laura A. Bolte,Johannes R. Björk,Jahlisa S. Hooiveld-Noeken,Ruth Board,Mark Harland,Julia Newton‐Bishop,Mark Harries,Joseph J. Sacco,Paul C. Lorigan,Heather May Shaw,Elisabeth G.E. de Vries,Rudolf S.N. Fehrmann,Rinse Karel Weersma
出处
期刊:BMC Cancer
[BioMed Central]
日期:2023-02-18
卷期号:23 (1): 166-166
被引量:9
标识
DOI:10.1186/s12885-023-10511-3
摘要
BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of melanoma and other cancers. However, no reliable biomarker of survival or response has entered the clinic to identify those patients with melanoma who are most likely to benefit from ICIs. Glycosylation affects proteins and lipids' structure and functions. Tumours are characterized by aberrant glycosylation which may contribute to their progression and hinder an effective antitumour immune response. METHODS: We aim at identifying novel glyco-markers of response and survival by leveraging the N-glycome of total serum proteins collected in 88 ICI-naive patients with advanced melanoma from two European countries. Samples were collected before and during ICI treatment. RESULTS: We observe that responders to ICIs present with a pre-treatment N-glycome profile significantly shifted towards higher abundancy of low-branched structures containing lower abundances of antennary fucose, and that this profile is positively associated with survival and a better predictor of response than clinical variables alone. CONCLUSION: While changes in serum protein glycosylation have been previously implicated in a pro-metastatic melanoma behaviour, we show here that they are also associated with response to ICI, opening new avenues for the stratification of patients and the design of adjunct therapies aiming at improving immune response.
科研通智能强力驱动
Strongly Powered by AbleSci AI